Clinical Trials Logo

Clinical Trial Summary

This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16 years).

Following confirmation of eligibility, including laboratory evidence of a fungal organism in the toenail, tavaborole topical solution was applied once daily to all affected toenails for a 48-week treatment period.

Clinical assessment of the extent of infection and safety assessments were performed periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after stopping the treatment).

A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small area of surrounding skin during the first 28 days. These subjects had blood samples analyzed to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical solution in children and adolescents.


Clinical Trial Description

This was an open-label study to evaluate the safety, tolerability, and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (DSO) of the toenail in pediatric subjects aged 6 to 16 years and 11 months. An eligible subject had a target great toenail (TGT) with at least 20% involvement, with a positive potassium hydroxide (KOH) wet mount and positive fungal culture for T. rubrum or T. mentagrophytes.

Eligible subjects applied tavaborole 5% topical solution, once daily to all affected toenails (the TGT as well as all other toenails having the clinical characteristics of onychomycosis) throughout the 48 week treatment period.

Subjects were evaluated at Screening, Baseline (Day 1), and at Weeks 2, 4, 8, 16, 24, 32, 40, 48, and 52. Each evaluation included a clinical assessment of the AEs and local tolerability evaluation.

Additional procedures were performed as follows:

- Mycology sampling at Screening, Week 24, and Week 52/early termination (ET);

- Clinical disease severity of the TGT at Screening, Week 24, and Week 52/ET;

- Safety laboratory testing at Baseline, Week 24, and Week 52/ET;

In this study, there was a PK subgroup of evaluable subjects aged 12 to 16 years and 11 months studied under maximal use conditions. Subjects in this maximal use subgroup applied the study drug on all 10 toenails, including up to 2 mm of the surrounding skin, for 28 days. On Day 15, a predose PK sample was collected to assess steady state trough level. On Day 29, the study drug application was done at the study site, and PK samples were collected prior to dosing, as well as 4, 6, 8, and 24 hours postdose on Days 29 to 30. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03405818
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 4
Start date October 22, 2015
Completion date July 27, 2017

See also
  Status Clinical Trial Phase
Completed NCT03098615 - Study Evaluating the Effect of Jublia on Dermatophytomas Phase 4
Recruiting NCT01666002 - Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser N/A
Completed NCT01180491 - A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis N/A
Terminated NCT01208168 - Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Phase 3
Terminated NCT01208129 - Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Phase 3
Completed NCT00385502 - A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail Phase 2
Completed NCT00253305 - Topical Gel Anti-Fungal Agent for Tinea Unguium Phase 2
Not yet recruiting NCT05809297 - Diode Laser and Photodynamic Therapy Vs. Ciclopirox. Phase 4
Completed NCT02588599 - A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis N/A
Recruiting NCT02436291 - Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Phase 4
Completed NCT01851590 - Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Phase 4
Completed NCT01452490 - Diode Laser Treatment of Onychomycosis N/A
Withdrawn NCT00938925 - Effectiveness of Podiatry Care on Onychomycosis (EPOCAON) N/A
Recruiting NCT00808366 - Efficacy and Safety of RV4104A Ointment in Onychomycosis N/A
Completed NCT00781820 - Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Phase 3
Completed NCT00768768 - Iontophoretic Application of Terbinafine Gel to the Large Toe Nail Phase 1
Completed NCT00777868 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis Phase 2
Recruiting NCT06074315 - Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis N/A
Completed NCT01039883 - A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule Phase 1
Suspended NCT05491603 - A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis Phase 2